ORIGINAL RESEARCH

Chronic Disease Burden After Congenital Heart Surgery: A 47-Year Population-Based Study With 99% Follow-Up

Alireza Raissadati, MD, PhD; Jari Haukka, MD, PhD; Tommi Päätilä, MD, PhD; Heta Nieminen, MD, PhD; Eero Jokinen, MD, PhD

BACKGROUND: Postoperative morbidity is an increasingly important outcome measure of patients who have undergone congenital heart surgery (CHS). We examined late postoperative morbidity after CHS on the basis of patients’ government-issued medical special reimbursement rights.

METHODS AND RESULTS: Between 1953 and 2009, 10,635 patients underwent CHS at <15 years of age in Finland. We excluded early deaths and mental disabilities. Noncyanotic and cyanotic defects were divided into simple and severe groups, respectively. We obtained 4 age-, sex-, birth time–, and hospital district–matched control subjects per patient. The Social Insurance Institution of Finland provided data on all medical special reimbursement rights granted between 1966 and 2012. Follow-up started at the first operation and ended at death, date of emigration, or December 31, 2012. A total of 8623 patients met inclusion criteria. Follow-up was 99.9%. A total of 3750 patients (43%) required special reimbursements rights for a chronic disease. Cardiovascular disease was the most common late morbidity among patients (28%), followed by obstructive pulmonary disease (9%), neurologic disease (3%), and psychiatric disease (2%). Heart failure (simple hazard ratio [HR], 56.3 [95% CI, 35.4–89.7]; severe HR, 918.0 [95% CI, 228.9–3681.7]) and arrhythmia (simple HR, 11.0 [95% CI, 7.1–17.0]; severe HR, 248.0 [95% CI, 61.3–1002.7]) were the most common cardiovascular morbidities. Hypertension was common among patients with coarctation of the aorta (13%; incidence risk ratio [RR], 8.9; 95% CI, 7.5–10.7). Psychiatric disease was more common among simple defects, particularly ventricular septal defects.

CONCLUSIONS: Chronic cardiac and noncardiac sequelae are common after CHS regardless of the severity of the defect, underscoring the importance of long-term follow-up of all patients after CHS.

Key Words: congenital heart disease ■ epidemiology ■ morbidity ■ outcome ■ pediatric cardiology

Congenital heart defects (CHDs) are the most common single-organ malformations, with a worldwide incidence of 9 to 13 of 1000 births annually.1 In Finland, ~1% of children are born with a CHD, of whom 60% require either surgical- or catheter-based correction or palliation. Previous register-based studies have established the improved operative mortality and late survival of this growing patient population.2 The increasing number of patients surviving to adulthood, however, necessitates more focus on their morbidity and quality of life as measures of the quality of care and outcome. We previously established that, although overall survival has improved, patients remain at risk for premature death attributable to both cardiac-related and nonrelated causes, underlining the importance of long-term follow-up regardless of the severity of the defect.3,4
In the current study, we combined data from 4 Finnish national registries to obtain a comprehensive profile of the postoperative morbidity of patients over a 5-decade time period in hopes of establishing the importance of postoperative follow-up of this patient group. Chronic morbidity was indirectly assessed by examining special reimbursement rights issued by the Finnish government to cover the cost of long-term medications for Finnish citizens.

### METHODS

The Finnish Ministry of Social Affairs and Health granted permission for this study, and the ethical committee approved the research protocol. The data that support the findings of this study are available from the author Tommi Pätilä (tommi.patila@hus.fi) at Helsinki University Central Hospital upon reasonable request.

### Nonstandard Abbreviations and Acronyms

- **ASD**: atrial septal defect
- **CHD**: congenital heart defect
- **CHS**: congenital heart surgery
- **COA**: coarctation of the aorta
- **HLHS**: hypoplastic left heart syndrome
- **PDA**: patent ductus arteriosus
- **TGA**: transposition of the great arteries
- **TOF**: tetralogy of Fallot
- **UVH**: univentricular heart
- **VSD**: ventricular septal defect

The Finnish Population Registry provided the status and time of death for all patients. The causes of death were gathered through autopsy reports and physician reports on a national scale. Statistics Finland supplied us with 4 age-, sex-, birth date–, and hospital district–matched control subjects per patient, along with causes of death for both patients and controls. Patients who were not included in the final analyses had their respective matched controls removed from the data. Informed consent from patients and the general population included in this study was waived because of the retrospective and anonymous nature of the investigation.

Every Finnish citizen is reimbursed for medications that treat chronic diseases. This reimbursement is granted by The Social Insurance Institution of Finland, which provides social security benefits to Finnish nationals. Morbidity was assessed by inspecting data on patients’ medical special reimbursement entitlements obtained from The Social Insurance Institution of Finland. Once a patient is granted a special reimbursement right, he/she can purchase the medication required for his/her chronic condition and receive substantial subsidies from the government for it, so that the final out-of-pocket amount remains affordable for the patient. As such, the special reimbursement right does not represent a time point when a patient purchases a
certain medication, but rather the time when the patient is diagnosed with a disease that grants him/her a special reimbursement right. Thus, for the sake of statistical analyses, you can use the date a special reimbursement right is acquired as the date a patient is diagnosed with a disease.

The criteria for special reimbursement entitlements depend on the medication and require a signed letter of medical necessity from the patient’s physician stating the indication of the drug. Each special reimbursement entitlement requires a specific attached *International Classification of Diseases (ICD)* diagnosis code. We obtained all special reimbursement entitlements and the associated *ICD-9* and *ICD-10* diagnoses between 1966 and 2012. Diagnoses were placed by both primary and specialty healthcare providers across the country.

**Study Design**

Diseases were grouped according to the indication of the special reimbursement entitlement, as presented in Table S1. Morbidity is presented as incidence of selected disease groups and compared between patients and controls by calculated rate and hazard ratios (HRs). We refrained from comparing time periods because of the heavy confounding effect from the change in special reimbursement policies throughout the years.

For the survival studies, follow-up ended at the date of the first special reimbursement entitlement within each disease group, death, emigration, or December 31, 2012. Each patient was assigned one primary diagnosis from a severity-based hierarchical list of cardiac defects: PDA, atrial septal defect (ASD), coarctation of the aorta (COA), ventricular septal defect (VSD), tetralogy of Fallot (TOF), transposition of the great arteries (TGA), hypoplastic left heart syndrome (HLHS), and univentricular heart (UVH). All remaining cardiac defects were collectively referred to as miscellaneous, including truncus arteriosus, atrioventricular canal, congenitally corrected TGA, pulmonary stenosis, total anomalous pulmonary venous return, partial anomalous pulmonary venous drainage, Ebstein anomaly, interrupted aortic arch, isolated valve defects, aortopulmonary window, vascular ring, trauma, pericardial disease, aortic aneurysms, and heart transplants. For patients with several cardiac defects, we chose the hierarchically more severe condition.5,6 To simplify the analyses, we dichotomized defect severity into simple (PDA, ASD, COA, and VSD) and severe (TOF, TGA, HLHS, and UVH) defects, according to the lack or presence of cyanosis, respectively. Detailed operative data for select defects are presented in Table S2.

**Statistical Analysis**

Incidence risk ratios (RRs) were obtained using Poisson regression with 95% CIs and were based on incidence rates of first events. HRs were obtained using matching group stratified Cox regression models. The matching reference units were accounted for as strata in the Cox model. Survival data are presented in the form of Kaplan-Meier plots. We used the date the first special reimbursement right for each disease group was granted as the event of interest. Death and emigration were treated as censoring events, such that special reimbursements were treated as events of interest until the day of death or emigration. Two-tailed *P* values were obtained with the log-rank test. In the estimation of hazard rate curves, we used Poisson regression with splines to produce smoothed curves with a 95% confidence envelope. We used B-spline basis matrix for a natural cubic spline with knots at 5, 15, 25, 35, and 45 years. SDs are reported with mean values. Analyses were performed using R program with the Epi package (R Development Core Team, Vienna, Austria, 2011) and IBM SPSS Statistics version 25.0 (SPSS, Inc, Chicago, IL).

**RESULTS**

**Patients**

After excluding PDA operations at <30 days of life, we identified 10,635 patients who underwent CHS between 1953 and 2009. After excluding early deaths (<30 days after first operation), patients with known intellectual disabilities, and all patients who underwent CHS before 1966, 8631 patients remained. Eight patients were excluded because of insufficient data. Thus, follow-up coverage was practically 100% with 8623 patients (Figure 1). Mean length of follow-up to death or end of the study was 23 years (SD, ±12.1 years; Table 1). The mean age at the end of follow-up was 26.6 years (SD, ±14.2 years; Table 1) for all patients.

The sex ratio was equal among simple and miscellaneous defects but male dominant among severe defects (Table 1). Mean age at the first operation was 4.2 years among simple defects and 1.4 years among severe defects (Table 1). Of patients who survived their operation, 6% died during their subsequent follow-up (Table 1). The cause of death was defect related in 49% of cases in the simple group (133/270) and 87% of cases in the severe group (234/263) (Table 1). The most common defect-related cause of death was heart failure in both groups (44% simple and 36% severe; Table 1).
Chronic Morbidity and Need for Medications

A total of 3750 patients (43%) had a chronic disease with an entitlement to special reimbursements for their medication. Results of the most common special reimbursement groups are presented by defect severity in Figure 2 and by subgroups in Table 2. The absolute numbers of patients with special reimbursements are detailed in Table S3. Cardiovascular disease was the most common indication for special reimbursement rights among patients (RR, 11.5 versus controls; 95% CI, 10.5–12.7), followed by obstructive pulmonary disease (RR, 1.8 versus controls; 95% CI, 1.6–1.9), endocrine disease (RR, 2.0 versus controls; 95% CI, 1.7–2.2), neurologic disease (RR, 2.5 versus controls; 95% CI, 2.1–2.9), and psychiatric disease (RR, 1.3 versus controls; 95% CI, 1.1–1.6). Chronic diseases were on average more common in the severe group.

Cardiovascular Disease

One fourth (28%) of patients required special reimbursement rights for cardiovascular medications (18% of patients with simple defects and 53% of those with severe defects). Heart failure was the most common indication for cardiovascular medication across all defect groups (Figure 2, Table 2, and Table S3). Overall, patients with severe defects were at a higher risk of heart failure compared with those with simple defects (Figure 2 and Table 2). One fifth (20%) of patients required medication for heart failure (12% of patients with simple defects, 40% of patients with severe defects, and 32% of patients with miscellaneous defects) (Table S3). Patients with univentricular morphological UVH (67%) and HLHS (84%) required special reimbursement rights for heart failure medications most frequently, whereas patients with PDA and ASD were at lowest risk (Table 2). Freedom from medication for heart failure diminished
markedly during the first year after the first CHS, with 30-year survival rates of 60% (95% CI, 57%–63%) among severe defects and 95% (95% CI, 94%–95%) among simple defects (Figure 3A). The derivative of the survival curve (hazard rate curve) for heart failure medication was trimodal in the severe group, indicating a high need for heart failure medication immediately and an estimated 15 and 30 years after the first operation (Figure 3B). Furthermore, patients with TGA and UVH required medication for heart failure on average 6 years (SD, 8.1 years) and 2.5 years (SD, 5.1 years) after their first operation, respectively.

Hypertension was the second most common indication for cardiovascular medication after CHS (patients versus controls: RR, 2.8; 95% CI, 2.4–3.2). The postoperative need for special reimbursement rights to cover antihypertensives was highest after surgery for COA (13.0%), HLHS (6.2%), and UVH (3.1%). Patients with COA who required antihypertensives were on average older at their first operation compared with those without antihypertensives (6.0±4.9 versus 3.3±4.9 years, respectively; P<0.0001). Freedom from special reimbursement rights for antihypertensives at 30 years after the first operation was 95% (95% CI, 94%–96%) in the simple group and 97% (95% CI, 96%–98%) in the severe group (Figure 3A).

Of the patient population, 3% received special reimbursement for antiarrhythmics. Patients in all defect groups except PDA required special reimbursement rights for antiarrhythmics more frequently than the control population (all patients: RR, 25.7 versus controls; 95% CI, 18.6–45.0), with a higher incidence in the severe defect group. Among simple defects, patients with VSD had the highest RR for antiarrhythmics (Table 2), whereas univentricular defects had the highest risk among severe defects (HLHS, 8.2%; and UVH, 16.0%). The 30-year freedom from reimbursement rights for antiarrhythmics was 87% (95% CI, 85%–90%; Figure 3A). The hazard rate curve for arrhythmia was trimodal in the severe group, with a peak of first special reimbursement rights within the first year and an estimated 15 to 20 and 25 to 30 years after the first operation (Figure 3B). Patients with ASD and COA required their first special reimbursement rights for antiarrhythmics an average of >20 years after their first operation, whereas patients with VSD, TOF, TGA, and UVH required them within an average of 11 to 18 years after their first operation.

Obstructive Pulmonary Disease

Obstructive pulmonary disease was the most common noncardiovascular indication for special reimbursement rights among patients (9%) and was more common among simple defects (490/5604; 9%; Table S3). Asthma was practically the only indication for special

| Table 1. Patient Characteristics |
|----------------------------------|
| **Characteristic**               | Simple | Severe | Miscellaneous |
| Defects, n (%)                   | 5604 (100) | 1440 (100) | 1579 (100) |
| PDA                              | 1522 (27)   | ...     | ...          |
| ASD                              | 1353 (24)   | ...     | ...          |
| COA                              | 1301 (23)   | ...     | ...          |
| VSD                              | 1428 (26)   | ...     | ...          |
| TOF                              | ...        | 587 (41) | ...          |
| TGA                              | ...        | 499 (34) | ...          |
| HLHS                             | ...        | 97 (7)   | ...          |
| UVH                              | ...        | 257 (18) | ...          |
| Miscellaneous                    | ...        | ...     | 1579 (100)  |
| Sex, n (%)                       | 3065 (55)   | 547 (38) | 752 (48)    |
| Women                            | 2539 (45)   | 893 (62) | 827 (52)    |
| Decade of first operation, n (%)  | 489 (9)     | 69 (5)  | 54 (3)      |
| 1966–1969                        | 1325 (23)   | 231 (16) | 208 (13)    |
| 1970–1979                        | 1378 (25)   | 334 (23) | 346 (22)    |
| 1980–1989                        | 1610 (29)   | 404 (28) | 520 (33)    |
| 2000–2009                        | 802 (14)    | 402 (28) | 451 (29)    |
| Age at first operation, mean±SD, y | 4.2±4.0    | 1.4±2.7 | 3.5±4.4    |
| <1 mo, n (%)                     | 482 (7)     | 543 (38) | 280 (18)    |
| 1–12 mo, n (%)                   | 1335 (24)   | 462 (32) | 494 (31)    |
| 1–4 y, n (%)                     | 1335 (24)   | 267 (18) | 275 (17)    |
| >4 y, n (%)                      | 2452 (44)   | 168 (12) | 530 (34)    |
| No. of operations, n (%)         | 3955 (70)   | 754 (52) | ...         |
| 1                               | 1394 (25)   | 327 (23) | ...         |
| 2                               | 204 (4)     | 247 (17) | ...         |
| >3                              | 49 (1)      | 110 (8)  | ...         |
| Status, n (%)                    | 5241 (93)   | 1168 (81) | 1556 (99)  |
| Alive                           | 270 (5)     | 263 (18) | 14 (1)      |
| Deceased                        | 133 (49)    | 234 (87) | 4 (29)      |
| Unknown                         | 3 (2)       | 1 (0)    | 0           |
| Reoperative                     | 30 (23)     | 65 (28)  | 0           |
| Cardiovascular                  | 9 (7)       | 30 (13)  | 0           |
| Sudden                          | 33 (25)     | 54 (23)  | 3 (75)      |
| Heart failure                   | 58 (44)     | 84 (36)  | 1 (25)      |
| Non–defect related              | 137 (61)    | 29 (13)  | 10 (71)     |
| Unknown                         | 93 (2)      | 9 (1)    | 0           |
| Follow-up, mean±SD, y           | 25.0±12.0   | 18.3±11.9 | 20.6±11.2 |
| Age at end of follow-up, mean±SD, y | 29.6±13.9  | 21.6±12.6 | 23.9±13.2  |
| Alive                           | 21.8±17.2   | 11.5±12.7 | 43.2±6.9   |
| Deceased                        | 29.1±14.1   | 19.7±13.2 | 24.1±13.3  |

ASD indicates atrial septal defect; COA, coarctation of the aorta; HLHS, hypoplastic left heart syndrome; PDA, patent ductus arteriosus; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; UVH, univentricular heart defect; and VSD, ventricular septal defect.
reimbursement rights for obstructive pulmonary disease and was significantly more common among patients compared with controls (RR, 1.8; 95% CI, 1.6–1.9 versus controls). Among simple defects, patients with VSD (8.8%) had the highest risk of asthma. Patients with HLHS had the highest risk, whereas patients with UVH had the highest absolute incidence of special reimbursement rights for asthma (8.9%) among severe defects. The 30-year freedom from special reimbursement rights for asthma was 91% (95% CI, 90%–92%) among simple defects and 91% (95% CI, 89%–92%) among severe defects (Figure 3A). The hazard rate was highest during the first 5 postoperative years (Figure 3B).

**Endocrine Disease**

All in all, 145 patients (1.7%) had a special reimbursement right for diabetes mellitus. Only patients with ASD had a higher risk for diabetes mellitus than the control population (Table 2). Patients with severe defects were at an increased risk of hypopituitarism (HR, 4.9; 95% CI, 3.4–7.2 versus controls), albeit with low absolute numbers (Table S3). There was also an increased risk for hypopituitarism among patients with ASD (Table S3).

**Neurologic and Psychiatric Disease**

Epilepsy was the most common neurologic indication for special reimbursement rights after CHS (Figure 2) and overall second most common noncardiovascular morbidity after CHS among all patients (Table S3). Patients with severe defects had a higher risk for requiring special reimbursement rights for epilepsy than those with simple defects (HR, 4.0; 95% CI, 2.7–5.9 versus controls), with 3.8% of patients with TGA, 3.5% of patients with UVH, and 8.2% of patients with HLHS requiring special reimbursement rights for antiepileptics. VSD had the highest risk of epilepsy among simple defects (Table 2).

This study does not include antidepressants because of the lack of a dedicated special reimbursement program. Regardless, patients with VSD required special reimbursement rights for psychiatric disease more often than the control population, particularly antipsychotics (Table 2). Patients with severe defects did not have a higher number of special reimbursements.
| Disease                          | Controls | PDA | ASD | CGA | VSD | TOF | TGA | HLHS | UWH | Miscellaneous |
|---------------------------------|----------|-----|-----|-----|-----|-----|-----|------|-----|---------------|
| Nephrotological                 | 2.4      | 6.7 | 2.8 | 6.0 | 2.5 | 0.0 | 13.6| 5.7  | 0.0 | 0.0           |
| (0.9–9.5)                       | (0.6–16.6)| 0.0 | ... | 13.6| 5.7 | 0.0 | ... | 0.0  | ... | 0.0           |
| Rheumatic                       | 43.5     | 42.7| 1.0 | 54.5| 1.3 | 46.9| 47.9| 62.8 | 98.9| 2.3           |
| (0.6–16.6)                      | (0.6–20.0)| 1.1 | (0.6–1.6)| 1.1 | (0.6–1.6)| 1.1 | (0.6–2.7)| 1.4 | (1.2–4.6)| 0.0  |
| Psychiatric                     | 71.3     | 90.1| 1.3 | 99.9| 1.5 | 84.8| 144.3| 62.9 | 876 | 1.2           |
| (0.9–17)                        | (10.0–20)| 1.2 | (0.8–1.7)| 2.3 | (1.5–2.8)| 0.9 | (0.4–1.8)| 1.2 | (0.6–2.5)| 0.0  |
| Alcohol or opioid addiction    | 1.5      | 2.2 | 1.5 | 3.0 | 2.0 | 3.1 | 6.8  | 5.8 | 0.0 | 0.0           |
| (0.2–11.4)                      | (0.3–15.3)| 1.7 | (0.2–12.0)| 2.1 | (0.3–13.4)| 1.3 | (1.7–20.1)| 6.2 | (0.1–20.1)| 0.0  |
| ADHD                            | 1.8      | 2.2 | 1.3 | 3.0 | 1.7 | 3.1 | 10.2| 5.8  | 10.9| 0.0           |
| (0.2–9.6)                       | (0.2–12.9)| 1.8 | (0.2–12.4)| 1.8 | (1.7–20.1)| 1.9 | (0.5–1.9)| 6.2 | (0.8–17.0)| 0.0  |
| Psychosis                       | 68.3     | 85.6| 1.3 | 93.8| 1.4 | 78.5| 130.6| 62.9 | 76.6| 1.1           |
| (0.9–17)                        | (1.0–20)| 1.2 | (0.8–1.7)| 1.9 | (1.4–2.7)| 1.9 | (0.5–1.9)| 1.1 | (0.5–2.4)| 0.0  |
| Neurological                    | 95.5     | 81.4| 1.5 | 125.4| 2.3 | 110.9| 145.9| 127.5| 213.9| 0.0           |
| (0.0–21.0)                      | (1.6–3.1)| 2.0 | (1.4–3.6)| 2.6 | (1.9–3.6)| 2.3 | (2.4–6.1)| 3.9 | (11.0–41.0)| 0.0  |
| Epilepsy                        | 49.0     | 67.7| 14  | 116.1| 2.4 | 101.3| 145.9| 119.4| 213.9| 4.4           |
| (0.0–20.0)                      | (1.7–3.3)| 2.1 | (2.4–3.0)| 3.0 | (2.4–4.1)| 2.4 | (0.8–6.9)| 4.4 | (11.4–46.4)| 5.3  |
| Other diseases                  | 41.5     | 74.4| 1.8 | 66.9| 1.6 | 72.1| 184.8| 248.5| 278.2| 12521.6       |
| (0.3–2.6)                       | (0.8–7.0)| 1.7 | (1.1–2.6)| 3.4 | (3.3–5.6)| 6.0 | (4.1–8.6)| 6.7 | (8.5–10.1)| 12521.6   |
| Glaucoma                        | 6.3      | 22.4| 3.6 | 27.1| 4.3 | 6.2  | 3.4  | 7.8  | 32.9 | 0.0           |
| (0.9–7.0)                       | (2.1–8.6)| 1.0 | (0.2–4.1)| 0.5 | (0.2–3.9)| 1.2 | (0.6–9.0)| 5.2 | (0.6–16.7)| 0.0  |
| Endocrine                       | 107.6    | 157.0| 1.5 | 202.8| 1.9 | 206.2| 190.5| 191.1| 109.7| 400.9         |
| (0.1–1.9)                       | (1.5–2.4)| 1.9 | (1.5–2.5)| 1.8 | (1.3–2.3)| 1.8 | (0.5–1.9)| 1.0 | (0.2–16.7)| 3.7  |
| Hypothalosphidism               | 0.4      | 2.2 | 5.9 | 3.0 | 79  | 6.8  | 7.8  | 7.8  | 0.0  | 0.0           |
| (0.0–5.6)                       | (0.8–61)| 0.0 | ... | 18.0| 18.0| 207  | 227  | 227  | 227  | 0.0           |
| Growth hormone                  | 1.1      | 8.9 | 7.9 | 6.0 | 5.3 | 21.8 | 13.6 | 7.8  | 0.0  | 131.8         |
| (2.4–20.6)                      | (1.1–24.9)| 19.3| (7.2–21.7)| 12.0| (3.7–3.0)| 6.9 | (0.9–4.3)| 0.0  | (147–197.0)| 56.2  |
| Hypopituitarism                 | 2.9      | 13.4| 4.6 | 30.1| 10.4| 28.1 | 20.5 | 15.6 | 10.9 | 132.9         |
| (0.9–11.4)                      | (4.9–21.5)| 9.7 | (4.5–21.0)| 7.1 | (2.9–17.6)| 5.4 | (1.3–27.8)| 3.8 | (6.2–339.3)| 45.8  |
| Hypogonadism                    | 14.4     | 26.9| 3.7 | 48.2| 6.7 | 197.7| 27.3 | 3.8  | 0.0  | 112.3         |
| (0.6–8.7)                       | (3.2–14.0)| 17.5| (17.8–42.6)| 1.4 | (1.4–10.3)| 0.0  | ... | 0.0  | ... | 112.3         |
| (0.6–10.3)                      | (0.8–7.6)| ... | ... | ... | ... | ... | ... | ... | ... | ...           |

Table 2. Incidence Rates and RRs of Selected Diseases by Defect Group, Obtained With a Poisson Regression Model With 95% CIs
Table 2. Continued

| Disease                  | Controls | PDA | ASD | COA | VSD | TOF | TGA | HLHS | UVH | Miscellaneous |
|--------------------------|----------|-----|-----|-----|-----|-----|-----|------|-----|--------------|
|                         | Incidence/100 PY | Incidence/100 PY | Incidence/100 PY | Incidence/100 PY | Incidence/100 PY | Incidence/100 PY | Incidence/100 PY | Incidence/100 PY | Incidence/100 PY | Incidence/100 PY |
| Hypothyroidism           | 25.2     | 58.6 | 2.3  | 0.9 | 0.9 | 82.4 | 3.3  | 62.9 | 2.5  | 32.8  | 132.0  | 3.4  | 84.5  | 3.4  |
| RR (95% CI)              | (1.5–3.5) | (0.4–1.8) | (2.1–5.1) | (1.4–4.1) | (0.7–3.7) | (1.1–10.5) | (0.7–3.7) | (1.4–4.1) | (0.7–3.7) | (1.1–10.5) | (0.7–3.7) | (1.1–10.5) | (0.7–3.7) | (1.1–10.5) |
| Diabetes mellitus        | 66.8     | 69.6 | 1.0  | 0.9 | 0.9 | 59.5 | 9.9  | 58.1 | 0.9  | 86.6  | 65.7  | 0.0  | 28.0  | 0.4  |
| RR (95% CI)              | (0.7–1.5) | (0.6–1.4) | (0.6–1.4) | (0.5–1.8) | (0.5–1.8) | (0.4–2.2) | (0.4–2.2) | (0.4–2.2) | (0.4–2.2) | (0.4–2.2) | (0.4–2.2) | (0.4–2.2) |
| Obstructive pulmonary disease | 210.1   | 330.8 | 1.6  | 1.8 | 2.5 | 345.9 | 1.8  | 381.3 | 1.8  | 408.3 | 322.8 | 2.2  | 459.9 | 2.2  |
| RR (95% CI)              | (1.3–1.9) | (1.5–2.2) | (1.5–2.2) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) | (1.4–2.6) |
| Cardiovascular           | 75.5     | 146.1 | 1.9  | 11.2 | 11.5 | 123.9 | 17.2 | 2662.0 | 35.3 | 91294.5 | 1210.1 | 99.0 | 15015.6 | 20.8 |
| RR (95% CI)              | (0.5–2.5) | (9.6–13.1) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) | (9.5–13.5) |
| Dyslipidemia             | 3.5      | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 0.0  | 84.4  | 23.9  | 0.3  | 0.9  | 0.3  |
| RR (95% CI)              | (0.1–6.3) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) |
| Arrhythmia               | 5.0      | 11.2 | 2.2  | 6.2  | 1.1  | 247.0 | 54.7 | 114.3 | 807.9 | 3.7   | 140.8 | 2.3  | 140.8 | 2.3  |
| RR (95% CI)              | (0.9–2.5) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) | (0.4–7.4) |
| Hypertension             | 61.6     | 88.0 | 1.4  | 8.9  | 9.9  | 276.8 | 65.7 | 102.1 | 1269.0 | 34.3 | 173.0 | 34.3 | 173.0 | 34.3 |
| RR (95% CI)              | (1.0–2.0) | (0.7–10.7) | (0.7–10.7) | (0.7–10.7) | (0.7–10.7) | (0.7–10.7) | (0.7–10.7) | (0.7–10.7) | (0.7–10.7) | (0.7–10.7) | (0.7–10.7) |
| Heart failure            | 4.2      | 43.6 | 10.5 | 297.2 | 297.2 | 53.4  | 12.8 | 12.8  | 71.4  | 673.2 | 161.8 | 23.8  | 39.5  | 23.8  |
| RR (95% CI)              | (6.0–18.4) | (7.2–23.1) | (7.2–23.1) | (7.2–23.1) | (7.2–23.1) | (7.2–23.1) | (7.2–23.1) | (7.2–23.1) | (7.2–23.1) | (7.2–23.1) | (7.2–23.1) |
| **RRs** were obtained by comparing the incidence of disease in each defect group with a sex-, age-, date of birth-, and hospital district–matched control population. ADHD indicates attention deficit hyperactivity disorder; ASD, atrial septal defect; COA, coarctation of the aorta; HLHS, hypoplastic left heart syndrome; PY, person years; PDA, patent ductus arteriosus; RR, incidence risk ratio; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; UVH, univentricular heart defect; and VSD, ventricular septal defect. **P<0.05.** |
Figure 3. Freedom from selected chronic diseases and time-dependent hazard rates by defect severity.
A, Kaplan-Meier curves depicting survival free of special reimbursement rights for the 4 most common indications for long-term medications among patients. B, Hazard rate with 95% CI for the 4 most common disease groups among patients as a function of time. Hazard rates were obtained using Poisson regression model comparing the simple and severe groups with 4 sex-, age-, date of birth-, and hospital district–matched control subjects. Shaded areas represent 95% CIs.
for psychiatric medications compared with the control population.

**Other Disease**

Rheumatic disease was more common in the severe defect group compared with the control population (Figure 2). Patients were not at higher risk for hematological, dermatological, or inflammatory bowel disease. Malignancies were common among both patients and the general population, with patients with ASD having a higher incidence of cancer than their matched controls (data not shown).

**Cardiovascular Morbidity by Defect Type and Operative Technique**

Thirteen percent of all patients with COA who underwent an end-to-end operation and 10% who underwent the subclavian flap operation required special reimbursement rights for antihypertensives. Of all VSD patients, 28% required special reimbursement rights for heart failure (26% of patients with single VSD and 38% of patients with multiple VSDs). Of all TOF patients, 24% required special reimbursement rights for heart failure medications (37% of those who underwent staged correction versus 20% of those who underwent primary correction). In the TGA group, 24% of all patients who underwent an arterial switch operation (ASO) required special reimbursement rights for heart failure medication versus 56% for those who underwent the Mustard operation and 44% who underwent the Senning. Similarly, only 6% of ASO patients required special reimbursement rights for antiarrhythmics (14/250) versus 11% of Mustard (8/73) and 14% of Senning patients (17/122).

**Cardiovascular Comorbidity**

Almost one fifth of patients with UVH (19%) who required medication for heart failure required treatment for coexisting arrhythmia. Similarly, 17% of patients with TGA who had an entitlement for heart failure medication also had an entitlement to antiarrhythmic medications. From another point of view, 80% and 69% of patients with UVH and TGA, respectively, who required antiarrhythmics also had an entitlement to heart failure medication. Similarly, 50% of patients with TOF, 43% of patients with VSD, and 60% of patients with COA with antiarrhythmics required simultaneous treatment for heart failure.

All patients with UVH and 90% of patients with TGA who required antihypertensives were also entitled to medication for heart failure. Of patients with TOF who required antihypertensives, 45% were also entitled to medications for heart failure, with a corresponding 15% rate for patients with COA.

**DISCUSSION**

In this population-based study, we found that pediatric patients with CHD who underwent CHS were at significant risk for late morbidity regardless of the severity of their cardiac defect. The need for medication to treat cardiovascular disease was particularly pronounced.

**Cardiovascular Morbidity**

The higher prevalence of cardiovascular disease in the severe defect group was not surprising given the higher cardiac strain associated with more complicated defects, residual cardiac abnormalities, multiple operations, and complex and prolonged surgery.

Heart failure is a common late sequela among patients with CHDs and was by far the most common chronic morbidity for all cardiac defects. A reported 40% to 50% of patients experience heart failure after the Fontan operation, representing the most common cause of death among this patient population. In this study, the incidence of heart disease was proportional to the severity of the defect, with most (72%) of patients with single-ventricle physiological features requiring medication for heart failure. According to the literature, 40% to 50% of patients with TGA who undergo an atrial switch operation experience right ventricular failure late after surgery. In our material, over a third of all TGA patients (36%) required heart failure medication, particularly patients who underwent an atrial switch operation (49%). The main reason is the abnormal cardiac physiological characteristics after the atrial switch operation. Patients with VSD are at risk for late aortic valve insufficiency, which may predispose to left ventricular strain if left untreated. Also, pulmonary hypertension predisposes to heart failure, which could be the case among some patients with VSD operated on during the earlier decades. In our material, patients with VSD were at highest risk of heart failure (28%) among simple defects.

Arrhythmias were common in all defect groups, except PDA, the correction of which does not involve manipulation of the cardiac tissue. Interestingly, patients with COA had a higher than expected risk of arrhythmia, with no correlation with hypertension and operative age. The cause of postoperative arrhythmias is multifactorial and involves damage to the cardiac conduction system, tissue hypoxia, primary myocardial disease, and residual defects. Arrhythmia and sudden deaths are recognized late complications after CHS, with >50% of all patients developing atrial arrhythmias before the age of 65 years and an overall increase in the cumulative risk with advanced age. Previous studies have established the high incidence of arrhythmias in patients with TGA.
who undergo atrial correction, with a corresponding low incidence among patients who undergo the ASO because of the lack of right atrial manipulation.\textsuperscript{14,15} In the current study, we observed that a lower proportion of patients with TGA who underwent ASO required antiarrhythmics postoperatively versus those who underwent an atrial switch operation. These results reflect those from our previous study, where we found that the switch to using the ASO method was paralleled by a decrease in the incidence of sudden deaths compared with the Senning and Mustard techniques.\textsuperscript{4} However, the shorter follow-up time of patients who underwent the ASO must be taken into account when interpreting these results. Patients with Fontan circulation have a reported 7\% to 39\% prevalence of postoperative arrhythmia.\textsuperscript{16} In the current study, patients with single-ventricle defects had the highest need for antiarrhythmics, at a prevalence of 14\%.

Patients with CHD are at risk of increased arterial stiffness.\textsuperscript{17,18} Häcker et al\textsuperscript{18} reported a significant correlation between low physical activity and increased arterial stiffness among this patient population, independent of the body mass composition. Moreover, studies have established a high prevalence of obesity among CHD patients, placing these patients at risk for metabolic syndrome.\textsuperscript{19,20} Accordingly, we observed an increased risk of hypertension among patients with COA, PDA, and HLHS. Recurrent hypertension is a common late sequela after surgery for COA, with reports of a 30\% to 75\% postoperative prevalence.\textsuperscript{21,22} In our material, 13\% of patients required antihypertensives after correction of COA at an average of 24 years after their surgery.

**Noncardiovascular Morbidity**

Obstructive pulmonary disease was the most common noncardiovascular late complication after CHS, despite excluding mentally disabled patients. Neurological complications have been associated even with nonoperated CHD patients and have been connected to potential abnormal regulation of prenatal cerebral oxygen supply.\textsuperscript{27} Also, de novo gene mutations may play a role in the neurodevelopmental outcome of these patients.\textsuperscript{29}

Psychiatric disorders were more common among patients with simple defects, particularly VSD (3\%), compared with the general population. Neuropsychological and mental health sequelae have been described after CHS, even among nonoperated patients.\textsuperscript{30,31} In our material, we found no correlation between the prevalence of psychiatric disorders and suicides. However, our data did not include antidepressants, because the special reimbursement right for depression requires psychotic symptoms to be granted, thus leaving out an important psychiatric disorder from the scope of the study. Moreover, it is recognized that specifically syndromes characterized by a combination of cardiac defects, abnormal facial features, thymic hypoplasia, cleft palate, and hypocalcemia (CATCH 22) predisposes to psychosis later in life.\textsuperscript{32} In the current study, however, we did not have data on the incidence of CATCH-22. Nevertheless, these results underscore the importance of screening for mental health disorders among both simple and severe defects.

Endocrine disorders were more common among the patient population. Hypogonadism and the need for growth hormone were particularly common among patients with COA. Coexisting congenital chromosomal defects and anomalies, such as Turner syndrome, can most likely explain most of these cases.

Finally, cancer is an increasingly recognized morbidity after CHS.\textsuperscript{33} Our material revealed a higher incidence for the need of cancer medications among patients with ASD compared with the general population. However, chemotherapies are mostly administered in a hospital setting and not purchased by patients, which excludes them from our data. As such, the full scope of cancer incidence among patients and the general population remains unknown in our material.

**LIMITATIONS**

First, the current study did not include patients who only underwent catheter interventions. Second, information on special reimbursement entitlements, although informative, does not reflect the actual incidence and prevalence of disease, particularly if left undiagnosed or untreated. Third, this study does not
CONCLUSIONS

In conclusion, both cardiac and noncardiac morbidity is common after pediatric CHS. More important, both simple and severe defects remain at significant risk for late morbidity, underscoring the importance of longitudinal follow-up in all patients after CHS.

ARTICLE INFORMATION

Received January 2, 2020; accepted March 25, 2020.

Affiliations
From the Department of Surgery and Cardiology, New Children’s Hospital, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland (A.R., T.P., H.N., E.J.); Boston Children’s Hospital, Boston, MA (A.R.); Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland (J.H.); and Department of Health Sciences, Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland (J.H.).

Acknowledgments
We thank Statistics Finland for assistance in obtaining the socioeconomic data of the patients in this study.

Sources of Funding
This study was funded by grants from the Emil Aaltonen Foundation and Medical Society of Finland.

Disclosures
None.

Supplementary Materials
Tables S1–S3

REFERENCES

1. Hoffman JIE, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890–1900.
2. Spector LG, Menk JS, Knight JH, McCracken C, Thomas AS, Vinocur JM, Oster ME, St Louis JD, Moller JH, Kochilas L. Trends in long-term mortality after congenital heart surgery. J Am Coll Cardiol. 2018;71:2434–2448.
3. Raissadati A, Nieminen H, Jokinen E, Saarinen H. Progress in late results among pediatric cardiac surgery patients. Circulation. 2015;131:347–353.
4. Raissadati A, Nieminen H, Haukka J, Saarinen H, Jokinen E. Late causes of death after pediatric cardiac surgery. J Am Coll Cardiol. 2016;68:487–498.
5. Nieminen HP, Jokinen EV, Saarinen HI. Late results of pediatric cardiac surgery in Finland: a population-based study with 96% follow-up. Circulation. 2001;104:570–575.
6. Carigren LE, Ericson A, Källén B. Monitoring of congenital cardiac de-fects. Pediatr Cardiol. 1987;8:247–256.
7. Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, Everitt MD, Gatzoulis M, Harris L, Hsu DT, et al. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2016;133:770–801.
8. Piran S, Veldtman G, Webb GD, Liu PP. Heart failure and ventricular dysfunction in patients with single and/or systemic right ventricles. J Am Coll Cardiol. 2002;39:130.
9. Norozi K, Wessel A, Alpers V, Amoldt JC, Geyer S, Buchhorn R. Incidence and risk distribution of heart failure in adolescents and adults with congenital heart disease after cardiac surgery. Am J Cardiol. 2006;97:1238–1243.
10. Couperus LE, Vlietinck HW, Zandstra TE, Kils P, Jongbloed MM, Holman ER, Zepffenfeld K, Hazekamp MG, Schalij MJ, Scherpborg R. Long-term outcome after atrial correction for transposition of the great arteries. Heart. 2019;105:790–796.
11. Amano M, Izuiri C, Imamura S, Ohashi N, Tamaki Y, Sochiro E, Miyake M, Tamura T, Kondo H, Kaitani K, et al. Progression of aortic regurgitation after subpulmonary infundibular ventricular septal defect repair. Heart. 2016;102:1479–1484.
12. Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation. 2007;115:534–545.
13. Bouchardy J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Bottega N, Marelli AJ. Atrial arrhythmias in adults with congenital heart disease. Circulation. 2009;120:1679–1686.
14. Gelatt M, Hamilton RM, McCrindle BW, Connelly M, Davis A, Harris L, Gow RM, Williams WG, Trusler GA, Freedom RM. Arrhythmia and mortality after the mustard procedure: a 30-year single-center experience. J Am Coll Cardiol. 1997;29:194–201.
15. Sun ZH, Happonen J-M, Bennenhagen R, Saarinen H, Pesonen E, Toivonen L, Jokinen E. Increased QT dispersion and loss of sinus rhythm as risk factors for late sudden death after Mustard or Senning procedures for transposition of the great arteries. Am J Cardiol. 2004;94:138–141.
16. d’Udekem Y, Iyengar AJ, Cochrane AD, Grigg LE, Ramsay JM, Wheaton GR, Penny DJ, Brizard CP. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007;116:157–164.
17. Boyes NG, Stickland MK, Fusinski S, Hogeweide E, Fries JTJ, Haykowsky MJ, Baril CL, Runalls S, Kakadekar A, Pharis S, et al. Physical activity modulates arterial stiffness in children with congenital heart disease: a CHAMPS cohort study. Congest Heart Dis. 2018;13:578–583.
18. Häcker A-L, Reiner B, Oberhofer R, Hager A, Ewert P, Müller J. Increased arterial stiffness in children with congenital heart disease. Eur J Prev Cardiol. 2017;25:103–109.
19. Pemberton VL, McCrindle BW, Barink S, Daniels SR, Barlow SE, Binns HJ, Cohen MS, Economos C, Faith MS, Gidding SS, et al. Report of the National Heart, Lung, and Blood Institute’s Working Group on...
obesity and other cardiovascular risk factors in congenital heart disease. *Circulation*. 2010;121:1153–1159.
20. Barbiero SM, D’Azevedo Sic C, Schuh DS, Cesa CC, de Oliveira Petkowicz R, Pellanda LC. Overweight and obesity in children with congenital heart disease: combination of risks for the future? *BMC Pediatr*. 2014;14:143.
21. Cohen M, Fuster V, Steele PM, Driscoll D, McGoon DC. Coarctation of the aorta: long-term follow-up and prediction of outcome after surgical correction. *Circulation*. 1989;80:840–845.
22. O’Sullivan JJ. Prevalence of hypertension in children after early repair of coarctation of the aorta: a cohort study using casual and 24 hour blood pressure measurement. *Heart*. 2002;88:163–166.
23. Matsuoka S, Tatara K, Usiroguchi Y, Kubo M, Akita H, Kuroda Y. Contribution of pulmonary hemodynamics on manifestation of allergic asthma in patients with congenital heart disease. *Acta Paediatr Jpn*. 1993;35:508–512.
24. Hayes D Jr. Idiopathic pulmonary arterial hypertension misdiagnosed as asthma. *J Asthma*. 2009;44:19–22.
25. Matsuoka S, Tatara K, Usiroguchi Y, Kubo M, Kuroda Y. Development of atopic asthma in infants with pulmonary congestion caused by congenital heart disease. *J Pediatr*. 1994;124:597–690.
26. Tsubata S, Ichida F, Miyazaki A, Hashimoto I, Hamamichi Y, Takayanagi M, Murakami O, Okada T. Bronchial hyper-responsiveness to inhaled histamine in children with congenital heart disease. *Acta Paediatr Jpn*. 1995;37:336–340.
27. Leisner MZ, Madsen NL, Ostergaard JR, Woo JG, Marino BS, Olsen MS. Congenital heart defects and risk of epilepsy: a population-based cohort study. *Circulation*. 2016;134:1689–1691.
28. Marino BS, Lipkin PH, Newburger JW, Peacock G, Gerdes M, Gaynor JW, Mussatto KA, Uzark K, Goldberg CS, Johnson WH, et al. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. *Circulation*. 2012;126:1143–1172.
29. Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, DePalma SR, McKean D, Wakimoto H, Gorham J, et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. *Science*. 2015;350:1262–1266.
30. Miatton M, De Wolf D, François K, Thiery E, Vingerhoets G. Neuropsychological performance in school-aged children with surgically corrected congenital heart disease. *J Pediatr*. 2007;151:73–78.
31. Olsen M, Sørensen HT, Hjortdal VE, Christensen TD, Pedersen L. Congenital heart defects and developmental and other psychiatric disorders. *Circulation*. 2011;124:1706–1712.
32. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. *Arch Gen Psychiatry*. 1999;56:940–945.
33. Olsen M, Garne E, Søværke C, Søndergaard L, Nissen H, Andersen HO, Hjortdal VE, Johnsen SP, Videnbak J. Cancer risk among patients with congenital heart defects: a nationwide follow-up study. *Cardiol Young*. 2013;23:40–46.
SUPPLEMENTAL MATERIAL
Table S1. List of diseases with accepted special reimbursement entitlements in Finland categorized by disease group.

| Cardiovascular                        |
|--------------------------------------|
| Atrial fibrillation                  |
| Chronic arrhythmia                   |
| Chronic heart failure                |
| Clopidogrel                           |
| Coronary artery syndrome and associated dyslipidemia |
| Hypertension                         |
| Pulmonary hypertension               |

| Dermatological                       |
|--------------------------------------|
| Generalized erythrodermia            |
| Psoriasis                            |
| Severe dermatitis                    |

| Endocrine                            |
|--------------------------------------|
| Adrenal insufficiency                |
| Diabetes insipidus                   |
| Diabetes type 2                      |
| Diabetes, insulin                    |
| Disorder in vitamin D metabolism    |
| Dyslipidemia                         |
| Familial dyslipidemia                |
| Growth hormone                       |
| Hypogonadism                         |
| Hypoparathyroidism                   |
| Hypopituitarism          |
|-------------------------|
| Hypothyroidism          |
| Osteoporosis            |
| Primary or secondary hyperparathyreosis |
| Severe pancreatic deficiency |

| Gastrointestinal        |
|-------------------------|
| Inflammatory bowel disease |

| Hematological           |
|-------------------------|
| Aplastic anemia         |
| Chronic coagulation disorders |
| Gammaglobulin deficiency |
| Isolated thrombocytopenia or granulocytopenia |
| Pernicious anemia / vB12 deficiency |

| Malignancies            |
|-------------------------|
| Breast cancer           |
| Cancer                  |
| Chronic myeloid leukemia or CLL |
| GIST, renal, or pancreatic cancer |
| Gynecological cancer    |
| Hematologic cancer      |
| Hematologic cancers     |
| Hepatic, renal, or thyroid cancer |
| Melanoma and renal carcinoma |
| Non-small cell lung cancer and pancreatic cancer |
| Other malignancies      |
| Category            | Conditions                                                                 |
|---------------------|-----------------------------------------------------------------------------|
| Prostate cancer     |                                                                             |
| Renal, pancreatic, breast cancer or tuberous sclerosis-associated astrocytoma |                                                                             |
| Renal, pancreatic, or breast cancer |                                                                             |
| **Metabolic**       |                                                                             |
| Obesity             |                                                                             |
| **Nephrological**   |                                                                             |
| Anemia related to chronic kidney failure |                                                                             |
| Chronic renal failure |                                                                             |
| Renal failure       |                                                                             |
| Uremia requiring dialysis |                                                                             |
| **Neurologic**      |                                                                             |
| Dementia (parkinson's or alzheimer) |                                                                             |
| Epilepsy            |                                                                             |
| Epilepsy or other seizures |                                                                             |
| Multiple sclerosis  |                                                                             |
| Myasthenia gravis   |                                                                             |
| Narcolepsy          |                                                                             |
| Parkinson's disease |                                                                             |
| Parkinsonism        |                                                                             |
| **Other**           |                                                                             |
| Anxiety related to mental disability |                                                                             |
| Congenital metabolic diseases |                                                                             |
| Cow milk protein allergy |                                                                             |
| Daily enteral feeding |                                                                             |
| Erectile dysfunction |                                                                             |
| **Glaucoma** |
| **Hyperuricemia** |
| **Malabsorbance** |
| **Neuralgia** |
| **Secondary anemias (several)** |
| **Severe malnutrition** |

**Psychiatric**
- **ADHD**
- **Alcohol or opioid addiction**
- **Antipsychotic**
- **Opioid addiction**
- **Psychosis**

**Pulmonary**
- **Chronic obstructive pulmonary disease**

**Rheumatic**
- **Gout**
- **Rheumatic disease**
- **Sarcoidosis**

**Transplantation**
- **Immunosuppressant**
- **Medications status post-transplantation**
Table S2. Surgical data on select defect groups.

| Defect          | 1960s | 1970s | 1980s | 1990s | 2000s | All   |
|-----------------|-------|-------|-------|-------|-------|-------|
| COA, n (%)      | 96 (100) | 346 (100) | 330 (100) | 305 (100) | 224 (100) | 1301 (100) |
| Operative technique |       |       |       |       |       |       |
| End-to-end      | 91 (95) | 297 (86) | 235 (71) | 218 (71) | 186 (83) | 1027 (79) |
| Subclavian flap | 0 (0) | 4 (1) | 72 (22) | 69 (23) | 1 (0) | 146 (11) |
| Other           | 5 (5) | 33 (9) | 13 (4) | 4 (1) | 6 (3) | 61 (5) |
| Patch aortoplasty | 0 (0) | 10 (3) | 5 (2) | 2 (1) | 11 (5) | 28 (2) |
| Extended end-to-end | 0 (0) | 0 (0) | 0 (0) | 8 (3) | 19 (9) | 27 (2) |
| Unknown         | 0 (0) | 2 (1) | 4 (1) | 3 (1) | 0 (0) | 9 (1) |
| Interposition graft | 0 (0) | 0 (0) | 1 (0) | 1 (0) | 1 (0) | 3 (0) |
| VSD, n (%)      | 60 (100) | 215 (100) | 348 (100) | 499 (100) | 306 (100) | 1428 (100) |
| Defect type     |       |       |       |       |       |       |
| Single          | 58 (97) | 196 (91) | 304 (87) | 402 (81) | 263 (86) | 1223 (86) |
| Multiple        | 1 (2) | 9 (4) | 32 (9) | 66 (13) | 36 (12) | 144 (10) |
| Other           | 1 (2) | 10 (5) | 12 (3) | 31 (6) | 7 (2) | 61 (4) |
| TOF, n (%)      | 47 (100) | 107 (100) | 142 (100) | 155 (100) | 136 (100) | 587 (100) |
| Operative technique |       |       |       |       |       |       |
| Primary         | 6 (13) | 80 (75) | 117 (82) | 115 (74) | 109 (80) | 427 (73) |
| Staged          | 41 (87) | 27 (25) | 25 (18) | 40 (26) | 22 (16) | 155 (26) |
| Other           | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (4) | 5 (1) |
| Defect type          | 12  | 136 | 133 | 126 |
|----------------------|-----|-----|-----|-----|
|                      | (100)| (100)| (100)| (100)| (100)| (100) |
| TGA, n (%)           |     |     |     |     |     |       |
| TGA, IVS             | 3 (25) | 59 (64) | 76 (56) | 71 (53) | 78 (62) | 287 (58) |
| TGA, VSD             | 5 (42) | 21 (23) | 32 (24) | 36 (27) | 28 (22) | 122 (24) |
| DORV, TGA type       | 0 (0) | 2 (2) | 16 (12) | 14 (11) | 13 (10) | 45 (9) |
| TGA, VSD, LVOTO      | 3 (25) | 2 (2) | 5 (4) | 8 (6) | 2 (2) | 20 (4) |
| Other                | 1 (8) | 5 (6) | 2 (1) | 2 (1) | 2 (2) | 12 (1) |
| TGA, IVS, LVOTO      | 0 (0) | 3 (3) | 4 (3) | 2 (2) | 0 (0) | 9 (2) |
| CCTGA                | 0 (0) | 0 (0) | 1 (0) | 0 (0) | 3 (2) | 4 (1) |
| Operative technique  |     |     |     |     |     |       |
| ASO                  | 0 (0) | 0 (0) | 18 (13) | 115 (87) | 117 (93) | 250 (50) |
| Senning              | 0 (0) | 12 (13) | 105 (77) | 5 (4) | 0 (0) | 122 (24) |
| Mustard              | 2 (17) | 70 (76) | 1 (1) | 0 (0) | 0 (0) | 73 (15) |
| Other or unknown     | 8 (67) | 6 (7) | 5 (4) | 3 (2) | 7 (5) | 29 (6) |
| Rastelli             | 2 (17) | 4 (4) | 7 (5) | 10 (7) | 2 (2) | 25 (5) |

COA, coarctation of the aorta; VSD, ventricular septal defect; TOF, tetralogy of Fallot; TGA, transposition of the great arteries; IVS, intact ventricular septum; DORV, double-outlet right ventricle; LVOTO, left ventricular outflow tract obstruction; CCTGA, congenitally corrected transposition of the great arteries.
Table S3. Number of patients with special reimbursement entitlements by defect severity and disease group.

| Disease Group              | Simple, n (%) | Severe, n (%) | Miscellaneous, n (%) | All, n (%) |
|----------------------------|---------------|---------------|----------------------|-----------|
| Metabolic                  | 6 (0.1)       | 0 (0.0)       | 0 (0.0)              | 6 (0.1)   |
| Hematological              | 5 (0.1)       | 2 (0.1)       | 3 (0.2)              | 10 (0.1)  |
| Nephrological              | 9 (0.2)       | 0 (0.0)       | 1 (0.1)              | 11 (0.1)  |
| Dermatologic               | 18 (0.3)      | 3 (0.2)       | 6 (0.4)              | 27 (0.3)  |
| Gastrointestinal           | 37 (0.7)      | 4 (0.3)       | 7 (0.4)              | 48 (0.6)  |
| Malignancies               | 46 (0.8)      | 2 (0.1)       | 10 (0.6)             | 58 (0.7)  |
| Transplantation            | 13 (0.2)      | 23 (1.6)      | 27 (1.7)             | 63 (0.7)  |
| Rheumatic                  | 71 (1.3)      | 18 (1.2)      | 27 (1.7)             | 116 (1.3) |
| Sarcoidosis                | 3 (0.1)       | 0 (0.0)       | 0 (0.0)              | 3 (0.0)   |
| Gout                       | 2 (0.0)       | 2 (0.1)       | 2 (0.1)              | 6 (0.1)   |
| Other rheumatic disease    | 66 (1.2)      | 16 (1.1)      | 25 (1.6)             | 107 (1.9) |
| Psychiatric                | 143 (2.5)     | 17 (1.2)      | 29 (1.8)             | 189 (2.2) |
| Alcohol or opioid addiction| 5 (0.1)       | 0 (0.0)       | 1 (0.1)              | 6 (0.1)   |
| ADHD                       | 6 (0.1)       | 1 (0.1)       | 4 (0.3)              | 11 (0.1)  |
| Psychosis                  | 132 (2.4)     | 16 (1.1)      | 24 (1.5)             | 172 (2.0) |
| Neurological               | 173 (3.1)     | 53 (3.7)      | 65 (4.1)             | 291 (3.4) |
| Myasthenia gravis          | 1 (0.0)       | 0 (0.0)       | 0 (0.0)              | 1 (0.0)   |
| Other neurological         | 4 (0.1)       | 0 (0.0)       | 0 (0.0)              | 4 (0.0)   |
| Multiple sclerosis         | 9 (0.2)       | 1 (0.1)       | 0 (0.0)              | 10 (0.1)  |
| Epilepsy                   | 159 (2.8)     | 52 (3.6)      | 65 (4.1)             | 276 (3.2) |
| Other diseases             | 202 (3.6)     | 152 (10.6)    | 169 (10.7)           | 523 (6.1) |
| Condition                                      | Count (Prevalence) |
|------------------------------------------------|--------------------|
| Glaucoma                                       | 23 (0.4) 4 (0.3) 11 (0.7) 38 (0.4) |
| Anxiety related to mental illness              | 30 (0.5) 3 (0.2) 18 (1.1) 51 (0.6) |
| Other                                          | 149 (2.6) 145 (10.1) 140 (8.9) 434 (5.0) |
| Endocrine                                      | 314 (5.6) 52 (3.6) 127 (8.0) 493 (5.7) |
| Diabetes type 2                                | 2 (0.0) 0 (0.0) 1 (0.1) 3 (0.0) |
| Hypoparathyroidism                             | 4 (0.1) 4 (0.3) 4 (0.3) 12 (0.1) |
| Other endocrine                                | 19 (0.3) 2 (0.1) 8 (0.5) 29 (0.3) |
| Growth hormone                                 | 17 (0.3) 4 (0.3) 13 (0.8) 34 (0.4) |
| Hypopituitarism                                | 33 (0.6) 7 (0.5) 21 (1.3) 61 (0.7) |
| Hypogonadism                                   | 52 (0.9) 2 (0.1) 14 (0.9) 68 (0.8) |
| Hypothyroidism                                 | 77 (1.4) 15 (1.0) 49 (3.1) 141 (1.6) |
| Insulin-treated diabetes                       | 110 (2.0) 18 (1.3) 17 (1.1) 145 (1.7) |
| Obstructive pulmonary disease                  | 490 (8.7) 113 (7.8) 160 (10.1) 763 (8.8) |
| Cardiovascular                                 | 1008 (18.0) 758 (52.6) 632 (40.0) 2398 (27.8) |
| Other cardiovascular                           | 1 (0.0) 3 (0.2) 1 (0.1) 5 (0.1) |
| Dyslipidemia                                   | 3 (0.1) 4 (0.3) 1 (0.1) 8 (0.1) |
| Coronary artery syndrome                       | 9 (0.2) 15 (1.0) 9 (0.6) 33 (0.4) |
| Arrhythmia                                     | 84 (1.5) 126 (8.8) 64 (4.1) 274 (3.2) |
| Hypertension                                   | 266 (4.7) 35 (2.4) 49 (3.1) 350 (4.1) |
| Heart failure                                  | 645 (11.5) 575 (39.9) 508 (32.2) 1728 (20.0) |